首页> 外文期刊>Journal of chemotherapy >Community-acquired pneumonia: aetiology, antibiotic resistance and prospects of phage therapy
【24h】

Community-acquired pneumonia: aetiology, antibiotic resistance and prospects of phage therapy

机译:社区获得的肺炎:病毒学,抗生素抗性和噬菌体疗法的前景

获取原文
获取原文并翻译 | 示例
           

摘要

Bacteria are the most common aetiological agents of community-acquired pneumonia (CAP) and use a variety of mechanisms to evade the host immune system. With the emerging antibiotic resistance, CAP-causing bacteria have now become resistant to most antibiotics. Consequently, significant morbimortality is attributed to CAP despite their varying rates depending on the clinical setting in which the patients being treated. Therefore, there is a pressing need for a safe and effective alternative or supplement to conventional antibiotics. Bacteriophages could be a ray of hope as they are specific in killing their host bacteria. Several bacteriophages had been identified that can efficiently parasitize bacteria related to CAP infection and have shown a promising protective effect. Thus, bacteriophages have shown immense possibilities against CAP inflicted by multidrug-resistant bacteria. This review provides an overview of common antibiotic-resistant CAP bacteria with a comprehensive summarization of the promising bacteriophage candidates for prospective phage therapy.
机译:细菌是社区获得性肺炎(CAP)最常见的病原,并利用多种机制逃避宿主免疫系统。随着抗生素耐药性的出现,导致CAP的细菌现在已经对大多数抗生素产生耐药性。因此,尽管CAP的发病率因患者接受治疗的临床环境而异,但CAP仍具有显著的发病风险。因此,迫切需要一种安全有效的常规抗生素替代品或补充品。噬菌体可能是一线希望,因为它们在杀死宿主细菌方面具有特异性。已经鉴定出几种噬菌体可以有效地寄生与CAP感染有关的细菌,并显示出良好的保护作用。因此,噬菌体已显示出对抗多药耐药细菌造成的CAP的巨大可能性。本文综述了常见的抗生素耐药CAP细菌,并对有望用于噬菌体治疗的候选噬菌体进行了全面总结。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号